← 返回

基于 DNMTs/TET2 平衡的野菊花复方抗肝细胞癌的配伍机制

英文原题:Compatibility mechanism of Chrysanthemi Indici Flos compound against hepatocellular carcinoma based on balance of DNMTs/TET2.

查看英文原题

Compatibility mechanism of Chrysanthemi Indici Flos compound against hepatocellular carcinoma based on balance of DNMTs/TET2.

PubMed 2026/03/09(内容时间) Chin Herb Med Q1 · IF 11.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究证实了 DNMTs/TET2 平衡关系作为中药复方配伍机制研究评价指标的合理性和可行性。在 DNMTs/TET2 平衡指导下筛选出的 YJHFF 具有保肝和肿瘤免疫功能,显示出良好的抗肝细胞癌作用。

研究思路结论见上方概要

目前,中药复方广泛用于肿瘤治疗。然而,由于当前疗效评价指标单一、简单化,且脱离中医理论指导,其疗效机制的阐明受到阻碍。因此,依据中医整体平衡观,基于DNA甲基转移酶/DNA去甲基化酶ten-eleven translocation 2(DNMTs/TET2)平衡关系,探讨菊花复方(YJHFF)抗肝细胞癌的配伍机制。

本研究在体外实验中筛选最佳配伍比例,以细胞活力和DNMTs/TET2平衡作为评价指标,考察单味药及不同配伍的复方对HepG2和H22细胞的影响。体内实验在H22肝癌原位移植模型小鼠上进行。治疗后,分别通过苏木精-伊红(HE)、TUNEL和Ki67免疫组化染色观察肿瘤组织。采用酶联免疫吸附试验检测血清中的氧化应激和肝功能指标。此外,通过免疫荧光染色检测TIL(肿瘤浸润淋巴细胞)的比例。采用RT-PCR检测肿瘤组织中DNMTs和TET2的mRNA表达水平。

体外实验结果显示,细胞增殖抑制率与DNMTs/TET2平衡的变化趋势高度一致,据此,本研究获得了最优配方YJHFF。体内实验中,YJHFF在5 g/kg剂量下的肿瘤生长抑制率为62.97%。肿瘤组织中可见广泛坏死、凋亡增加及增殖活性受抑。此外,血清SOD活性显著升高,MDA、ALT、AST和AFP水平显著降低,提示YJHFF可系统性缓解氧化应激并改善肝功能。同时,CD3+、CD4+和CD8+ T淋巴细胞浸润显著增加,表明机体抗肿瘤免疫应答增强。最后,RT-PCR分析证实,其抗肿瘤作用与DNMTs/TET2表达调控及表观遗传平衡重建这一核心机制密切相关。

展开英文摘要原文

At present, traditional Chinese medicine (TCM) compounds is widely used in tumor therapy. However, due to the current single and simplistic efficacy evaluation indicators that are detached from the guidance of TCM theory, the elucidation of its mechanisms of efficacy is hindered. Therefore, the compatibility mechanism of Chrysanthemi Indici Flos compound (YJHFF) against hepatocellular carcinoma based on DNA methyltransferases/DNA demethylase ten-eleven translocation 2 (DNMTs/TET2) balanced relationship was explored according to the concept of the overall balance of TCM.

This study screened the best compound compatibility ratio in the in vitro experiments, cell viability and DNMTs/TET2 balance were used as evaluation indicators to investigate the effects of single herb and different compatibility of compound on HepG2 and H22 cells. In vivo experiments were conduct on H22 liver orthotopic transplantation model mice. After treatment, the tumor tissues were observed by hematoxylin-eosin (HE), TUNEL and Ki67 immunohistochemical staining, respectively. The oxidative stress and liver function indicators in serum were detected by enzyme-linked immunosorbent assay. In addition, the proportion of tumor-infiltrating lymphocytes was detected by immunofluorescence staining. The mRNA expression levels of DNMTs and TET2 in tumor tissues were detected by RT-PCR.

The results of in vitro experiments showed that the cell proliferation inhibition rate was highly consistent with the change trend of DNMTs/TET2 balance, accordingly, this study obtained the optimal formula YJHFF. In the in vivo experiments, the tumor growth inhibition rate of YJHFF in 5 g/kg was 62.97%. Extensive necrosis, increased apoptosis and inhibited proliferation activity were observed in tumor tissue. Furthermore, the serum SOD activity was significantly increased, MDA, ALT, AST and AFP levels were significantly decreased, suggesting YJHFF could systematically alleviated oxidative stress and improved liver function. Besides, the infiltration of CD3 + , CD4 + and CD8 + T lymphocytes increased significantly, indicating that the body's anti-tumor immune response was enhanced. Finally, RT-PCR analysis confirmed that antitumor effects were closely related to the core mechanism of DNMTs/TET2 expression regulation and reconstruction of epigenetic balance.

This work confirmed the rationality and feasibility of the DNMTs/TET2 balance relationship as an evaluation indicator for the study of the compatibility mechanism of TCM compounds. The YJHFF screened under the guidance of DNMTs/TET2 balance has liver protection and tumor immune function, showing good anti-hepatocellular carcinoma effect.

论文信息

作者
He Z、Guo C、Zhang F、Li F、Zhou Y、Ma L、Wang X、Bi Y
单位
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.China
期刊
Chinese herbal medicines2026 Jul
原文标识
PubMed 42488830 · DOI 10.1016/j.chmed.2026.03.003